These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 35589915)

  • 1. Effects of Lanthionine Ketimine-5-Ethyl Ester on the α-Synucleinopathy Mouse Model.
    Yazawa A; Hensley K; Ohshima T
    Neurochem Res; 2022 Aug; 47(8):2373-2382. PubMed ID: 35589915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lanthionine ketimine ester improves outcome in an MPTP-induced mouse model of Parkinson's disease via suppressions of CRMP2 phosphorylation and microglial activation.
    Togashi K; Hasegawa M; Nagai J; Kotaka K; Yazawa A; Takahashi M; Masukawa D; Goshima Y; Hensley K; Ohshima T
    J Neurol Sci; 2020 Jun; 413():116802. PubMed ID: 32244093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lanthionine ketimine ethyl ester partially rescues neurodevelopmental defects in unc-33 (DPYSL2/CRMP2) mutants.
    Hubbard C; Benda E; Hardin T; Baxter T; St John E; O'Brien S; Hensley K; Holgado AM
    J Neurosci Res; 2013 Sep; 91(9):1183-90. PubMed ID: 23825043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tau is required for progressive synaptic and memory deficits in a transgenic mouse model of α-synucleinopathy.
    Singh B; Covelo A; Martell-Martínez H; Nanclares C; Sherman MA; Okematti E; Meints J; Teravskis PJ; Gallardo C; Savonenko AV; Benneyworth MA; Lesné SE; Liao D; Araque A; Lee MK
    Acta Neuropathol; 2019 Oct; 138(4):551-574. PubMed ID: 31168644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A cell-penetrating ester of the neural metabolite lanthionine ketimine stimulates autophagy through the mTORC1 pathway: Evidence for a mechanism of action with pharmacological implications for neurodegenerative pathologies.
    Harris-White ME; Ferbas KG; Johnson MF; Eslami P; Poteshkina A; Venkova K; Christov A; Hensley K
    Neurobiol Dis; 2015 Dec; 84():60-8. PubMed ID: 25779968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lanthionine ketimine ester promotes locomotor recovery after spinal cord injury by reducing neuroinflammation and promoting axon growth.
    Kotaka K; Nagai J; Hensley K; Ohshima T
    Biochem Biophys Res Commun; 2017 Jan; 483(1):759-764. PubMed ID: 27965088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lanthionine ketimine ester provides benefit in a mouse model of multiple sclerosis.
    Dupree JL; Polak PE; Hensley K; Pelligrino D; Feinstein DL
    J Neurochem; 2015 Jul; 134(2):302-14. PubMed ID: 25846048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A derivative of the CRMP2 binding compound lanthionine ketimine provides neuroprotection in a mouse model of cerebral ischemia.
    Nada SE; Tulsulkar J; Raghavan A; Hensley K; Shah ZA
    Neurochem Int; 2012 Dec; 61(8):1357-63. PubMed ID: 23036362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of the CRMP2 activator lanthionine ketimine ethyl ester on oligodendrocyte progenitor cells.
    Savchenko V; Kalinin S; Boullerne AI; Kowal K; Lin SX; Feinstein DL
    J Neuroimmunol; 2019 Sep; 334():576977. PubMed ID: 31177034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteomic identification of binding partners for the brain metabolite lanthionine ketimine (LK) and documentation of LK effects on microglia and motoneuron cell cultures.
    Hensley K; Christov A; Kamat S; Zhang XC; Jackson KW; Snow S; Post J
    J Neurosci; 2010 Feb; 30(8):2979-88. PubMed ID: 20181595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic deletion of nitric oxide synthase 2 ameliorates Parkinson's disease pathology and neuroinflammation in a transgenic mouse model of synucleinopathy.
    Kim J; Han JY; Lee Y; Kim K; Choi YP; Chae S; Hoe HS
    Mol Brain; 2023 Jan; 16(1):7. PubMed ID: 36647152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroprotective and neurotrophic effects of Lanthionine Ketimine Ester.
    Marangoni N; Kowal K; Deliu Z; Hensley K; Feinstein DL
    Neurosci Lett; 2018 Jan; 664():28-33. PubMed ID: 29128626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of p38α MAPK restores neuronal p38γ MAPK and ameliorates synaptic degeneration in a mouse model of DLB/PD.
    Iba M; Kim C; Kwon S; Szabo M; Horan-Portelance L; Peer CJ; Figg WD; Reed X; Ding J; Lee SJ; Rissman RA; Cookson MR; Overk C; Wrasidlo W; Masliah E
    Sci Transl Med; 2023 May; 15(695):eabq6089. PubMed ID: 37163617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A derivative of the brain metabolite lanthionine ketimine improves cognition and diminishes pathology in the 3 × Tg-AD mouse model of Alzheimer disease.
    Hensley K; Gabbita SP; Venkova K; Hristov A; Johnson MF; Eslami P; Harris-White ME
    J Neuropathol Exp Neurol; 2013 Oct; 72(10):955-69. PubMed ID: 24042198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphorylation of tau and alpha-synuclein in synaptic-enriched fractions of the frontal cortex in Alzheimer's disease, and in Parkinson's disease and related alpha-synucleinopathies.
    Muntané G; Dalfó E; Martinez A; Ferrer I
    Neuroscience; 2008 Apr; 152(4):913-23. PubMed ID: 18343584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prominent microglial inclusions in transgenic mouse models of α-synucleinopathy that are distinct from neuronal lesions.
    Tanriöver G; Bacioglu M; Schweighauser M; Mahler J; Wegenast-Braun BM; Skodras A; Obermüller U; Barth M; Kronenberg-Versteeg D; Nilsson KPR; Shimshek DR; Kahle PJ; Eisele YS; Jucker M
    Acta Neuropathol Commun; 2020 Aug; 8(1):133. PubMed ID: 32787922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lanthionine ketimine-5-ethyl ester provides neuroprotection in a zebrafish model of okadaic acid-induced Alzheimer's disease.
    Koehler D; Shah ZA; Hensley K; Williams FE
    Neurochem Int; 2018 May; 115():61-68. PubMed ID: 29475037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unbiased Proteomics of Early Lewy Body Formation Model Implicates Active Microtubule Affinity-Regulating Kinases (MARKs) in Synucleinopathies.
    Henderson MX; Chung CH; Riddle DM; Zhang B; Gathagan RJ; Seeholzer SH; Trojanowski JQ; Lee VMY
    J Neurosci; 2017 Jun; 37(24):5870-5884. PubMed ID: 28522732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased phosphorylation of collapsin response mediator protein-2 at Thr514 correlates with β-amyloid burden and synaptic deficits in Lewy body dementias.
    Xing H; Lim YA; Chong JR; Lee JH; Aarsland D; Ballard CG; Francis PT; Chen CP; Lai MK
    Mol Brain; 2016 Sep; 9(1):84. PubMed ID: 27609071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurotoxic conversion of beta-synuclein: a novel approach to generate a transgenic mouse model of synucleinopathies?
    Fujita M; Sekigawa A; Sekiyama K; Sugama S; Hashimoto M
    J Neurol; 2009 Aug; 256 Suppl 3():286-92. PubMed ID: 19711118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.